INHIBIKASE THERAPEUTICS INC (IKT) Stock Balance Sheet
NASDAQ:IKT - Nasdaq - US45719W2052 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | 56.49M | 9.17M | 7.19M | 40.75M | 13.95M | |||
| Marketable Securities | 41.05M | 4.09M | 15.86M | N/A | N/A | |||
| Receivables | N/A | 0.00 | 40.00K | 110.00K | N/A | |||
| Other Current Assets | 907.80K | 959.00K | 1.28M | 1.61M | 830.00K | |||
| Total Current Assets | 98.45M | 14.21M | 24.37M | 42.47M | 14.78M | |||
| Non-Current Assets | ||||||||
| PPE Net | 148.50K | 295.60K | 570.00K | N/A | N/A | |||
| Other Non-Current Assets | N/A | N/A | N/A | N/A | 0.00 | |||
| Total Non-Current Assets | 148.60K | 295.60K | 570.00K | 0.00 | 0.00 | |||
| TOTAL ASSETS | 98.60M | 14.51M | 24.94M | 42.47M | 14.78M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | 250.00K | 40.00K | |||
| Accrued Expenses | 2.79M | 2.41M | 2.54M | 2.72M | 630.00K | |||
| Accounts Payable | 943.00K | 646.80K | 1.15M | 1.09M | 1.72M | |||
| Other Current Liabilities | 0.00 | 381.80K | N/A | 0.00 | 2.33M | |||
| Total Current Liabilities | 3.73M | 3.44M | 3.70M | 4.05M | 4.72M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 280.00K | |||
| Other Non-Current Liabilities | 0.00 | 90.10K | 210.00K | N/A | N/A | |||
| Total Non-Current Liabilities | 0.00 | 90.10K | 200.00K | 0.00 | 280.00K | |||
| TOTAL LIABILITIES | 3.73M | 3.53M | 3.90M | 4.05M | 5.00M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -94.42M | -66.90M | -47.87M | -29.82M | -15.03M | |||
| Additional Paid In Capital | 189.25M | 77.87M | 68.78M | 68.21M | 24.81M | |||
| Common Shares | 69.40K | 6.20K | 30.00K | 30.00K | 10.00K | |||
| Other Shareholders' Equity | -37.30K | 900.00 | 100.00K | N/A | N/A | |||
| Shares Outstanding | 69.36M | 6.19M | 4.20M | 4.19M | 1.68M | |||
| Tangible Book Value per Share | 1.37 | 1.77 | 5.01 | 9.17 | 5.82 | |||
| Total Shareholders' Equity | 94.87M | 10.98M | 21.04M | 38.42M | 9.78M | |||
| TOTAL LIABILITIES AND EQUITY | 98.60M | 14.51M | 24.94M | 42.47M | 14.78M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | 0.03 | |||
| Current Ratio | 26.37 | 4.13 | 6.59 | 10.49 | 3.13 | |||
| Return On Assets (ROA) | -27.91% | -131.17% | -72.37% | -34.82% | -19.28% | |||
| Return On Equity (ROE) | -29.01% | -173.34% | -85.79% | -38.50% | -29.14% | |||
All data in USD , ROIC based on taxRate of 0.21